Veritas In Silico

August 3, 2026

Company Name: Veritas In Silico Inc.
Representative: Shingo NAKAMURA,
Representative Director and CEO
Listed on: TSE Growth
Stock Ticker Code: 130A
Contact Person: Tsuneo GODA,
Executive Officer, General Manager,
Corporate Planning Division
Email: ir@veritasinsilico.com

Joint Patent Application Filed for lncRNA-Targeting Drugs

Veritas In Silico Inc. (hereinafter referred to as "the Company") is pleased to announce progress in its Joint Research on nucleic acid drugs (antisense oligonucleotides: ASOs[*1]) with Mitsubishi Gas Chemical Company, Inc. (hereinafter referred to as "MGC", "the Joint Research"). The Joint Research was previously highlighted in the announcement dated July 3, 2025, titled "Mitsubishi Gas Chemical and Veritas In Silico Announce Joint Research Agreement for Drug Discovery and Establishment of Manufacturing Methods for Nucleic Acid Drugs".

As a significant milestone in the Joint Research, the Company, in collaboration with MGC, has filed a joint composition-of-matter patent application for a novel drug candidate targeting lncRNA[*2]. Details are as follows:

- Title of Invention: Nucleic Acid Drugs and Use Thereof
- Patent Application Number: № 2026-179989
- Applicants: Veritas In Silico Inc., Mitsubishi Gas Chemical Company, Inc.
- Gene name: lncRNA H19
- Target disease: Cancers associated with lncRNA H19
- Novelty: First-in-class (no existing approved drug)
- Modality: Nucleic acid drug (antisense oligonucleotides: ASO)
- Estimated development period: 8-10 years (development schedule to be detailed)
- Development strategy: Targeting cancer patients harboring lncRNA H19-associated malignancies—a population of a viable market scale—the Company aims to obtain regulatory approval through relatively small-scale clinical trials, while keeping partnering opportunities in perspective. Post-approval, the Company intends to pursue label expansion and global market development.

The Company utilizes its proprietary drug discovery platform, aibVIS[*3], which enables mRNA-targeted drug discovery, to collaborate with partner companies in creating small-molecule therapeutics—the largest segment in the pharmaceutical market. Concurrently, the Company is committed to in-house research and development of nucleic acid therapeutics, a segment projected to yield the highest growth potential. This dual approach aligns with the Company's growth strategy of exploring mRNA-targeted small-molecule therapeutics while addressing unmet medical needs in rare diseases using nucleic acid therapeutics as the optimal modality. Furthermore, this business strategy leverages the versatility of the Company's proprietary technologies—which are applicable to both small-molecule and nucleic acid drug discovery—to further differentiate the Company from its competitors.

While nucleic acid therapeutics conventionally target mRNA, the Joint Research has targeted lncRNA to unlock a broader spectrum of therapeutic efficacy. Unlike conventional drug targets such as proteins and mRNA, lncRNA possesses distinct characteristics and plays a crucial regulatory role in gene expression. Identifying aberrant lncRNA activity and developing novel therapeutics that can either suppress or enhance its functions holds significant promise. Demonstrating that the Company's technology can successfully target lncRNA as effectively as mRNA in this Joint Research is expected to substantially broaden the scope of drug discovery domains to which the Company can contribute in the future.

The target gene, H19, is known as a long non-coding RNA that does not encode proteins. H19 is highly expressed during embryonic development and has been reported to be involved in cancer cell proliferation, invasion, metastasis, and treatment resistance. Therefore, targeting H19 with nucleic acid therapeutics is expected to suppress tumor progression and provide synergistic benefits when used in combination with existing therapies. Moreover, its extremely low expression in normal cells makes H19 a highly promising target for the creation of nucleic acid therapeutics.

To date, the Company has independently acquired and filed multiple patents for nucleic acid therapeutics. By applying and refining the Company's latest insights and technologies specifically for H19, the Company has successfully developed a highly potent antisense oligonucleotide (ASO) that does not require complex chemical modifications, culminating in this patent application. Furthermore, the newly filed nucleic acid therapeutic, when combined with "Perfusio" (patented in December 2025)—the Company’s proprietary drug delivery system[*4] targeted for commercial launch in fiscal year 2027—holds the potential to pave the way for future treatment modalities that deliver enhanced therapeutic efficacy with minimized systemic side effects.

In the Joint Research, the principles of Quality by Design (QbD)[*5] have been integrated from the early research phase. By developing the manufacturing methods and processes for ASOs in parallel with drug discovery research, the Company aims to create nucleic acid therapeutics that are highly active and exhibit low toxicity, while securing quality, reliability, and cost-

efficiency in commercial manufacturing. This integrated approach is intended to expedite the establishment of manufacturing methods and accelerate progression into clinical trials.

● Impact on Future Business Performance of VIS

The filing of this patent application represents the successful creation of an in-house pipeline (for FY2026), which is set as a Key Performance Indicator (KPI) under the Company's growth strategy.

Over the projected development period (estimated at 8 to 10 years), the Company expects to incur research and development expenses in line with the progress of the Company's drug discovery research. R&D expenditures for the fiscal year ending December 31, 2026, have already been factored into the consolidated financial forecasts announced on February 12, 2026. Therefore, no revisions to the forecast are anticipated as a result of this announcement.

In case any matters requiring disclosure arise in the future, they will be promptly disclosed.

● Glossary for Reference

*1 ASO (Antisense Oligonucleotide): A class of nucleic acid drugs designed to bind complementarily to a target mRNA, thereby inhibiting protein translation or promoting mRNA degradation.

*2 lncRNA (long non-coding RNA): RNA molecules that do not translate into proteins but consist of relatively long nucleotide sequences. They are known to regulate cell gene expression and play key roles in cellular proliferation, differentiation, and oncogenesis. In recent years, specific lncRNAs have been linked to the onset and progression of various diseases, drawing significant attention as novel drug discovery targets.

*3 aibVIS: The Company's proprietary drug discovery platform that integrates all digital and drug discovery technologies required for mRNA-targeted therapeutics. Developed as an upgraded version of the conventional platform ibVIS®, aibVIS incorporates advanced and enhanced capabilities of multiple dedicated AI (artificial intelligence) models. It performs structural analysis utilizing AI and the supercomputer "Fugaku."

*4 Drug Delivery System (DDS): A system designed to deliver active pharmaceutical ingredients selectively to target tissues or organs. While conventional methods chemically conjugate targeting molecules to drugs or encapsulate them in lipid bilayers, the Company's proprietary system utilizes an arterial catheter to approach the target organ and physically deliver the therapeutic, while selectively recovering the drug via a venous catheter. This localized approach achieves targeted drug delivery without relying on complex chemical modifications of the drug itself, thereby preventing systemic circulation.

*5 QbD (Quality by Design): A systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, ensuring that quality is built into the product from the design phase.

For Further Information, Contact:

- Mitsubishi Gas Chemical Company, Inc. Nucleic Acid CDMO Service (AXELPHEX™)
  Special Website: https://axelphex.com/
- Veritas In Silico Website Inquiry Form : https://www.veritasinsilico.com/en/contact/